BRPI1012140A2 - métodos e composições relacionados a fusões de alk para o diagnóstico e o tratamento de cânceres - Google Patents

métodos e composições relacionados a fusões de alk para o diagnóstico e o tratamento de cânceres

Info

Publication number
BRPI1012140A2
BRPI1012140A2 BRPI1012140A BRPI1012140A BRPI1012140A2 BR PI1012140 A2 BRPI1012140 A2 BR PI1012140A2 BR PI1012140 A BRPI1012140 A BR PI1012140A BR PI1012140 A BRPI1012140 A BR PI1012140A BR PI1012140 A2 BRPI1012140 A2 BR PI1012140A2
Authority
BR
Brazil
Prior art keywords
fusions
alkaline
treatment
methods
cancer diagnosis
Prior art date
Application number
BRPI1012140A
Other languages
English (en)
Portuguese (pt)
Inventor
David Haut
Eric Dahlhauser
Josh Nickols
Kim Norman
Original Assignee
Insight Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Genetics Inc filed Critical Insight Genetics Inc
Publication of BRPI1012140A2 publication Critical patent/BRPI1012140A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI1012140A 2009-05-15 2010-05-17 métodos e composições relacionados a fusões de alk para o diagnóstico e o tratamento de cânceres BRPI1012140A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17893709P 2009-05-15 2009-05-15
PCT/US2010/035147 WO2010132888A2 (en) 2009-05-15 2010-05-17 Methods and compositions relating to fusions of alk for diagnosing and treating cancer

Publications (1)

Publication Number Publication Date
BRPI1012140A2 true BRPI1012140A2 (pt) 2016-05-03

Family

ID=43085621

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012140A BRPI1012140A2 (pt) 2009-05-15 2010-05-17 métodos e composições relacionados a fusões de alk para o diagnóstico e o tratamento de cânceres

Country Status (11)

Country Link
US (2) US20120208713A1 (enExample)
EP (2) EP3133167B1 (enExample)
JP (2) JP2012526563A (enExample)
CN (1) CN102575287B (enExample)
AU (1) AU2010248782B2 (enExample)
BR (1) BRPI1012140A2 (enExample)
CA (1) CA2762108A1 (enExample)
ES (1) ES2700098T3 (enExample)
MX (1) MX338297B (enExample)
RU (1) RU2562144C2 (enExample)
WO (1) WO2010132888A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
JP2015508644A (ja) * 2012-02-08 2015-03-23 インサイト ジェネティクス インコーポレイテッド 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物
CN102888452B (zh) * 2012-05-18 2014-08-27 复旦大学附属肿瘤医院 一种筛查alk融合基因的方法
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
WO2014026133A1 (en) * 2012-08-09 2014-02-13 Insight Genetics, Inc. Methods and compositions relating to alk for diagnosing and treating inflammatory breast and other human cancers
CA2882759C (en) * 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
CN103805687B (zh) * 2012-11-09 2016-06-01 益善生物技术股份有限公司 Alk融合基因检测的pcr引物、试剂盒和液相芯片
RU2509153C1 (ru) * 2012-11-28 2014-03-10 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Способ анализа транслокаций eml4-alk, ассоциированных с чувствительностью рака легкого к противоопухолевой таргетной терапии
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
EP2986736B1 (en) * 2013-04-17 2019-09-18 Life Technologies Corporation Gene fusions and gene variants associated with cancer
CN103290120B (zh) * 2013-05-24 2015-03-25 厦门艾德生物医药科技有限公司 一种用于检测alk基因表达的探针、引物及试剂盒
CN106414768B (zh) * 2014-03-27 2020-05-29 生命技术公司 与癌症相关的基因融合体和基因变异体
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
WO2016106701A1 (zh) * 2014-12-31 2016-07-07 深圳华大基因股份有限公司 检测非小细胞肺癌的qRT-PCR引物、探针、芯片、试剂盒、应用和方法
CN107532209A (zh) * 2015-04-17 2018-01-02 豪夫迈·罗氏有限公司 检测基因融合的多重pcr
CN107022610B (zh) * 2017-04-01 2019-02-05 常州桐树生物科技有限公司 肿瘤驱动基因的检测芯片及其应用
KR101987065B1 (ko) * 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
RU2681165C1 (ru) * 2017-12-01 2019-03-04 Общество с ограниченной ответственностью "Научно-Исследовательский Центр Молекулярной Биомедицины" (ООО "НИЦ МолБиоМед") Способ определения активности теломеразы методом двойной амплификации теломерных повторов в реальном времени
CN111235272B (zh) * 2020-01-10 2023-07-07 厦门艾德生物医药科技股份有限公司 一次性检测肺癌多重基因突变的组合物及其应用
CN113005200B (zh) * 2021-04-14 2023-07-04 深圳乐土生物科技有限公司 一种检测肉瘤融合基因突变的引物组合物、试剂盒及应用
CN114807124B (zh) * 2022-04-01 2023-09-12 上海信诺佰世医学检验有限公司 一种检测alk融合基因的引物和探针组合物、试剂盒及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU8126694A (en) * 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
GB0319227D0 (en) * 2003-08-15 2003-09-17 Novartis Ag Organic compounds
ATE429495T1 (de) * 2005-01-25 2009-05-15 Sky Genetics Inc Nukleinsäuren für die apoptose von krebszellen
WO2006085326A2 (en) * 2005-02-10 2006-08-17 Siano Mobile Silicon Ltd. System and method for mitigating memory requirements
WO2006094073A2 (en) * 2005-03-02 2006-09-08 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
US20060286558A1 (en) * 2005-06-15 2006-12-21 Natalia Novoradovskaya Normalization of samples for amplification reactions
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
JP5562640B2 (ja) * 2007-04-13 2014-07-30 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ

Also Published As

Publication number Publication date
JP2012526563A (ja) 2012-11-01
RU2011151049A (ru) 2013-06-20
WO2010132888A3 (en) 2011-01-20
MX338297B (es) 2016-04-11
EP3133167B1 (en) 2018-09-12
RU2562144C2 (ru) 2015-09-10
AU2010248782A1 (en) 2012-01-19
CN102575287B (zh) 2016-11-16
CA2762108A1 (en) 2010-11-18
AU2010248782B2 (en) 2015-06-11
MX2011012162A (es) 2012-01-30
CN102575287A (zh) 2012-07-11
US20120208713A1 (en) 2012-08-16
EP3133167A1 (en) 2017-02-22
JP2016052332A (ja) 2016-04-14
US20170183743A1 (en) 2017-06-29
EP2432900A2 (en) 2012-03-28
ES2700098T3 (es) 2019-02-14
JP6397833B2 (ja) 2018-09-26
WO2010132888A2 (en) 2010-11-18
EP2432900A4 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
BRPI1012140A2 (pt) métodos e composições relacionados a fusões de alk para o diagnóstico e o tratamento de cânceres
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
EP2513299A4 (en) ADIPEOUS FABRIC DECELLULARIZED
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BR112012004176A2 (pt) implemento para cuidado oral
DK3097925T3 (da) Farmaceutisk sammensætning
EP2429400A4 (en) QUANTITATIVE ENDOSCOPY
BRPI1004940A2 (pt) composição farmacêutica
ES2397671T8 (es) Procedimiento para preparar voriconazol
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
ES2700843T8 (es) Herramientas dentales para cirugía guiada
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112013016207A2 (pt) composições para cuidados orais
BRPI1015939A2 (pt) composição farmacêutica
BRPI1008932A2 (pt) cápsula endoscópica
PT2512502T (pt) Métodos e composições para supressão de tumores
BR112012005680A2 (pt) composição de higiene pessoal
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
DE112010000740A5 (de) Endoskop
BRPI1008253A2 (pt) Metoso para tratar biomassa
BRPI1005919A2 (pt) composição imunogênica
BR112013006796A2 (pt) ferramenta para perfurar o tecido ósseo
BR112012008141A2 (pt) arquivo cirúrgico
EP2440937A4 (en) A diagnostic method

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.